HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons von Poloznikov, Andrey A, Nersisyan, Stepan A, Hushpulian, Dmitry M, Kazakov, Eliot H, Tonevitsky, Alexander G, Kazakov, Sergey V, Vechorko, Valery I, Nikulin, Sergey V, Makarova, Julia A, Gazaryan, Irina G

Volltext

Harnessing the Therapeutic Potential of the Nrf2/Bach1 Signaling Pathway in Parkinson's Disease von Ahuja, Manuj, Kaidery, Navneet Ammal, Dutta, Debashis, Attucks, Otis C, Kazakov, Eliot H, Gazaryan, Irina, Matsumoto, Mitsuyo, Igarashi, Kazuhiko, Sharma, Sudarshana M, Thomas, Bobby

Volltext

Identification of a potent Nrf2 displacement activator among aspirin-containing prodrugs von Gaisina, Irina N., Hushpulian, Dmitry M., Gaisin, Arsen M., Kazakov, Eliot H., Ammal Kaidery, Navneet, Ahuja, Manuj, Poloznikov, Andrey A., Gazaryan, Irina G., Thatcher, Gregory R.J., Thomas, Bobby

Volltext